Robert Landry has served as a member of our Board of Directors since February 2025.
Previously, Mr. Landry served as the Chief Financial Officer at Regeneron Pharmaceuticals, where he was responsible for all financial operations, including investor relations, information technology, competitive intelligence, and global non-manufacturing facilities. During his tenure, he helped guide the company as it grew substantially in market capitalization and workforce, oversaw two public acquisitions, Checkmate Pharmaceuticals and Decibel Therapeutics, and established affiliates around the world.
Prior to joining Regeneron Pharmaceuticals, Mr. Landry spent 25 years at Wyeth and Pfizer, Inc., where he held numerous corporate and operational roles, including Corporate Treasurer, Director of Pharmaceutical Marketing and Sales, Senior Vice President of Finance, and Chief Financial Officer of Wyeth Australia and New Zealand. Mr. Landry started his career at Coopers & Lybrand, now PricewaterhouseCoopers LLP.
Currently Mr. Landry serves on the Board of Directors of Zymeworks, a global biotechnology company developing novel therapeutics to address difficult-to-treat diseases.
Mr. Landry was a Certified Public Accountant in New York and received a Bachelor of Business Administration from the University of Notre Dame.
What is Robert E. Landry's net worth?
The estimated net worth of Robert E. Landry is at least $677.50 thousand as of September 11th, 2026. Mr. Landry owns 9,184 shares of Cytokinetics stock worth more than $677,504 as of September 13th. This net worth estimate does not reflect any other investments that Mr. Landry may own. Learn More about Robert E. Landry's net worth.
How do I contact Robert E. Landry?
Has Robert E. Landry been buying or selling shares of Cytokinetics?
In the last ninety days, Robert E. Landry has sold $74,660.00 in shares of Cytokinetics stock. Most recently, Robert E. Landry sold 1,000 shares of the business's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $74.66, for a transaction totalling $74,660.00. Following the completion of the sale, the director now directly owns 9,184 shares of the company's stock, valued at $685,677.44. Learn More on Robert E. Landry's trading history.
Who are Cytokinetics' active insiders?
Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Andrew Callos (EVP), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Robert Landry (Director), Sung Lee (EVP, Chief Financial Officer), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), Wendell Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?
During the last year, insiders at the biopharmaceutical company sold shares 69 times. They sold a total of 533,142 shares worth more than $35,875,007.22. The most recent insider tranaction occured on September, 11th when Director
Robert E. Landry sold 1,000 shares worth more than $74,660.00. Insiders at Cytokinetics own 2.6% of the company.
Learn More about insider trades at Cytokinetics. Information on this page was last updated on 9/11/2026.
